This educational program is intended for oncology nurses and other healthcare professionals who care for patients with cancer.
The goal of this activity is to improve the knowledge, confidence, and competence of oncology nurses to understand and explain available clinical data on novel and emerging approaches for early stages of cancer and how these data and treatments will affect clinical outcomes, as well as how to promote health equity among patients with cancer.
Upon completion of this activity, participants should be able to:
Evaluate key clinical data and current indications for immune checkpoint inhibitor–based neoadjuvant or adjuvant therapy in patients with earlier stages of solid tumor cancers
Apply a focused nursing assessment navigating the implications of immuno-oncology in early stages of cancer and knowledge of adverse events unique to immune checkpoint inhibitors
Communicate with patients about the expectations of early treatment with ICIs on their overall prognosis, along with the importance of frequent monitoring and early reporting of immune-related adverse events
Identify patients most likely to benefit from treatment with immune checkpoint inhibitor therapy or enrollment on clinical trials, considering existing barriers that create racial and socioeconomic disparities in care
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Marianne Davies, DNP, ACNP, FAAN, has no relevant financial relationships to disclose.
Ronan Kelly, MD, MBA: consultant/advisor/speaker: Astellas, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, EMD Serono, Grail, Ipsen, Merck, Novartis, Novocure, Takeda, Toray; researcher: Lilly.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 1.5 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from July 17, 2023, through July 16, 2024:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.5 contact hours.